Investigators Test Immunotherapy Combo in HCC

Rachel Narozniak
Published: Friday, Aug 02, 2019
Stacey Stein, MD

Stacey Stein, MD

Investigators hope to expand frontline treatment options for patients with hepatocellular carcinoma (HCC) via the phase III IMbrave150 study (NCT03434379), which is exploring the synergistic potential of immunotherapy and the immunomodulatory potential of a VEGF inhibitor in locally advanced, metastatic or unresectable HCC. In IMbrave150, patients are being randomized 2:1 to receive either a doublet of atezolizumab (Tecentriq) and bevacizumab (Avastin) or standard-of-care single-agent sorafenib (Nexavar; Figure).1
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Clinical Practice Connections™: From Diagnosis to Emerging Immunotherapeutic Options: Understanding the Burden and Risks in Peanut AllergySep 28, 20191.0
Enduring CME activity from the School of Breast Oncology®: 2018 Mid-Year Video UpdateSep 28, 20192.0
Publication Bottom Border
Border Publication
x